Today Morgan Stanley Reiterates a “Overweight” Rating on Zimmer Biomet Holdings (NYSE:ZBH) and a $136 Target Price

November 15, 2017 - By Stephen Andrade

 Today Morgan Stanley Reiterates a

Zimmer Biomet Holdings (NYSE:ZBH) Rating Reaffirmed

New York: In a report shared with investors and clients on 2 November, Morgan Stanley reconfirmed their “Overweight” rating on Zimmer Biomet Holdings (NYSE:ZBH) shares. They now have a $136 target price per share on the company. Morgan Stanley’s target gives a potential upside of 22.48 % from the company’s last stock price.

Zimmer Biomet Holdings Inc (NYSE:ZBH) Ratings Coverage

Among 30 analysts covering Zimmer Biomet Holdings (NYSE:ZBH), 21 have Buy rating, 2 Sell and 7 Hold. Therefore 70% are positive. Zimmer Biomet Holdings has $158 highest and $92 lowest target. $131.86’s average target is 18.75% above currents $111.04 stock price. Zimmer Biomet Holdings had 76 analyst reports since August 27, 2015 according to SRatingsIntel. The company was maintained on Friday, April 28 by Needham. As per Monday, July 10, the company rating was maintained by BMO Capital Markets. The company was maintained on Friday, July 28 by Oppenheimer. The firm has “Buy” rating by RBC Capital Markets given on Sunday, July 23. Jefferies maintained Zimmer Biomet Holdings Inc (NYSE:ZBH) on Thursday, June 29 with “Buy” rating. Needham maintained Zimmer Biomet Holdings Inc (NYSE:ZBH) rating on Friday, January 29. Needham has “Buy” rating and $129 target. On Friday, July 29 the stock rating was maintained by Needham with “Buy”. Oppenheimer maintained the shares of ZBH in report on Wednesday, July 12 with “Buy” rating. SunTrust initiated it with “Buy” rating and $155 target in Thursday, August 11 report. The rating was maintained by Jefferies on Thursday, July 27 with “Buy”.

About 120,857 shares traded. Zimmer Biomet Holdings Inc (NYSE:ZBH) has declined 0.44% since November 15, 2016 and is downtrending. It has underperformed by 17.14% the S&P500.

Analysts expect Zimmer Biomet Holdings Inc (NYSE:ZBH) to report $2.10 EPS on January, 30.They anticipate $0.04 EPS change or 1.87 % from last quarter’s $2.14 EPS. ZBH’s profit would be $425.21 million giving it 13.23 P/E if the $2.10 EPS is correct. After having $1.72 EPS previously, Zimmer Biomet Holdings Inc’s analysts see 22.09 % EPS growth.

Zimmer Biomet Holdings, Inc. is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products. The company has market cap of $22.48 billion. The Company’s products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. It has a 34.63 P/E ratio. The Firm manages its activities through three geographic operating divisions: the Americas, consisting principally of the United States and other North, Central and South American markets; EMEA, consisting principally of Europe and the Middle East and African markets, and Asia Pacific, consisting primarily of Japan and other Asian and Pacific markets.

More notable recent Zimmer Biomet Holdings Inc (NYSE:ZBH) news were published by: Nasdaq.com which released: “Zimmer Biomet Holdings Inc. Q3 Income Falls 3%” on November 01, 2017, also Investorplace.com with their article: “Quant Score Makes Zimmer Biomet Holdings, Inc. (ZBH) a Sell” published on October 24, 2017, Nasdaq.com published: “David Dreman Buys Total SA, Zimmer Biomet Holdings Inc, The Travelers Inc …” on November 15, 2017. More interesting news about Zimmer Biomet Holdings Inc (NYSE:ZBH) were released by: Nasdaq.com and their article: “Zimmer Biomet Holdings is Now Oversold (ZBH)” published on November 03, 2017 as well as Prnewswire.com‘s news article titled: “Zimmer Biomet Announces US Launch of Vitality®+ and Vitalâ„¢ Spinal Fixation …” with publication date: October 25, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.